AzTrials
AzTrials

Allergy to FishABCFish2NCT02666092

Anisakis Blastocystis Cryptosporidium Fish Serology

An observational study of Allergy to Fish and Allergy, run by University Hospital, Lille at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Anisakidae frequently infect fish species that are commonly eaten by humans. Some of them are recognized as zoonotic diseases agents, and have a high impact on human health. Infestation results from the ingestion of living larvae from contaminated fishes. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Allergy to Fish, Allergy, Anisakis
What is being tested?
Questionnaire and Detection of anti-Anisakis and anti-fish antibodies
How many people
105 participants
Where
1 siteFrance
Study dates
Feb 2015to Jan 2017
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: The recruited population will include: * 51 patients with fish allergy * 51 matched control subjects (sex, age +/- 5 years)

Who may be able to join

  • ALLERGIC PATIENTS:
  • Previous serological assessment for anti-Anisakis or anti-fish antibodies detection (ImmunoCap and/or immunoelectrophoresis) in Lille University Hospital Center, and volume of serum conserved ≥500 µl
  • Allergic manifestations after contact with fish (asthma, allergic rhinitis, conjunctivitis, chronic or acute urticaria, dermatitis/eczema, eosinophilic gastroenteritis, gingivostomatitis, angioedema, bronchospasm, anaphylaxis)
  • CONTROL SUBJECTS:
  • Serological assessment for infectious disease during a routine occupational health consultation in Lille University Hospital Center
  • Absence of fish allergy

Who cannot join

  • Pregnant or breast-feeding female
  • Patient with no social insurance
  • Patient unwilling to comply with the protocol
  • Patient unable to understand the study and its objectives
  • Patient under guardianship

Trial locations and contacts

1 site in 1 country.

France1 site
  • CHRU

    Lille

Other trials in France

About this study

Official title: Protists and Nematodes Fish Parasites: From Their Circulation in Ecosystems to Their Impact on Human Health - Role of Anisakidae and/or Fish Flesh Antigens in Fish Allergies.

Anisakidae frequently infect fish species that are commonly eaten by humans. Some of them are recognized as zoonotic diseases agents, and have a high impact on human health.

Infestation results from the ingestion of living larvae from contaminated fishes. It can be asymptomatic or symptomatic, resulting in acute gastric, acute intestinal or chronic forms. Allergic manifestations are frequently encountered in gastric forms, but allergic symptoms can also occur in isolation, after ingestion of Anisakidae antigens contained in raw or cooked fish, and may masquerade as fish allergy.

In this study, we aim to characterize the relationship between Anisakidae and/or fish sensitization and the presence of allergic manifestations in patients recruited in the general population and presenting fish allergy resulting from ingestion, cutaneous or respiratory contact. We will also determine the respective role of Anisakidae or fish sensitization in patients with fish allergy. Then, we will determine the prevalence of previous Anisakidae infections among these patients and a matched control population. We will also compare the performances of serological tests (ImmunoCAP, immunoelectrophoresis and Western Blot) for the diagnosis of Anisakidae allergy or infection. Lastly, we will explore the relationship between domestic exposure to Anisakidae or fish antigens and the occurrence of associated pathologies (Anisakidae or fish allergy/sensitization; Anisakidae infection).

Read the detailed description

First, 51 patients with fish allergy will be recruited from the Parasitology-Mycology and Immunology Laboratories of Lille University Hospital databases (serology for anti-Anisakis or anti-fish detection). Then, clinical (characteristics of allergic manifestations) and epidemiological (domestic exposure to fish) data will be collected, and anti-fish or Anti-Anisakis antibodies will be detected using ImmunoCAP (IgE), or ImmunoCAP, immunoelectrophoresis, Western Blot, respectively. Similar serological tests will be performed for a control group of 51 matched subjects who will be recruited among Lille University Hospital workers.

Being tested
Questionnaire, Detection of anti-Anisakis and anti-fish antibodies
Keywords
IgE, Immunoelectrophoresis, Western Blot, ImmunoCAP
Medical subject headings
Hypersensitivity, Anisakiasis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • QuestionnaireOther

    Questionnaire on domestic exposure to fish, and, for patients with fish allergy, on the characteristics of clinical manifestations)

  • Detection of anti-Anisakis and anti-fish antibodiesBiological

    Anti-fish IgE will be detected using ImmunoCAP. Anti-Anisakis antibodies will be detected using ImmunoCAP (IgE), immunoelectrophoresis (precipitins) and Western Blot.

Study groups in NCT02666092
Study groupRoleWhat they receive
Fish allergy51 subjects presenting allergic manifestations after digestive, cutaneous, or respiratory contact with fish will be recruited. Interventions will include: * A questionnaire on domestic exposure to fish, and on the characteristics of clinical manifestations * A detection of anti-Anisakis and anti-fish antibodies
Receives: Other: Questionnaire; Biological: Detection of anti-Anisakis and anti-fish antibodies
Control51 subjects presenting no allergic manifestations after contact with fish. Interventions will include: * A questionnaire on domestic exposure to fish * A detection of anti-Anisakis and anti-fish antibodies
Receives: Other: Questionnaire; Biological: Detection of anti-Anisakis and anti-fish antibodies

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. the frequency of anti-Anisakis and/or anti-fish IgE by serum analysis

    comparison between subjects with fish allergy and a matched control population, presenting no fish allergy.

    Measured: contact by phone during 30 min at only visit (inclusion)

Secondary outcomes (5)
  1. anti-Anisakis and/or anti-fish IgE level by serum analysis

    Comparison between subjects with fish allergy and a matched control population, presenting no fish allergy.

    Measured: contact by phone during 30 min at only visit (inclusion)

  2. the frequency of anti-Anisakis and anti-fish IgE in patients with fish allergy by serum analysis

    Measured: contact by phone during 30 min at only visit (inclusion)

  3. nomber of subjects of previous Anisakidae infections

    questionnaire-based diagnosis, supported by serological testing between patients with fish allergy and a matched control population, presenting no fish allergy.

    Measured: contact by phone during 30 min at only visit (inclusion)

  4. Measure of the performances of serological tests

    Comparison of the performances of serological tests (ImmunoCAP, immunoelectrophoresis and Western Blot) for the diagnosis of Anisakidae allergy or infection.

    Measured: at work medical visit (inclusion)

  5. The frequency of domestic exposure to fish parasites antigens by questionnaire

    It will be compared between Anisakis or fish allergic/sensitized subjects and non-allergic/non sensitized subjects.

    It will be compared between patients with or without previous Anisakidosis. Fish exposure will be determined taking into account the handled fish species and the local prevalences of fish parasites.

    Measured: contact by phone during 30 min at only visit (inclusion)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Jan 2016 (estimated)
  2. Study startFeb 2015
  3. Primary completionJan 2017
  4. Study completionJan 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Retrospective
Enrolment
105 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02666092
Sponsor's protocol ID
2013_43
Other IDs
2014-A00855-42
Acronym
ABCFish2
Status last verified
Jan 2017
First submitted
25 Jan 2016
Last updated
18 Jan 2017
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Allergy to Fish and Allergy, run by University Hospital, Lille at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Jan 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

the frequency of anti-Anisakis and/or anti-fish IgE by serum analysis (time frame: contact by phone during 30 min at only visit (inclusion)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jan 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in